Skip to main content

Bruce Alan Sullenger, PhD

Joseph W. and Dorothy W. Beard Professor of Experimental Surgery, in the School of Medicine
Professor of Surgery
Associate Professor in Molecular Genetics and Microbiology
Professor of Pharmacology and Cancer Biology
Professor of Neurosurgery
Office: 1079 MSRB II, Box 103035, Durham, NC 27710
Campus Mail: DUMC Box 103035, Durham, NC 27710

The main focus of my translational research laboratory is to develop RNA based therapeutic agents for the potential treatment of a range of diseases. To this end, we have and will continue to take advantage of the fact that RNA is not just a passive carrier of genetic instructions inside of cells during the conversion of information from DNA to RNA to protein. Rather, RNA is an extremely versatile biological macromolecule. Certian RNAs can bind to specific protiens with high affinities, while others can for catalytic centers and perform enzymatic reactions. These facets of RNA coupled with the ease with which RNA can be manipulated in vitro make it a very powerful and unique therapeutic agent whose potential is largely untapped. Durring our endeavors, we plan to work closely with the members of the Molecular Therapeutics program as well as other faculty at the Duke University Medical Center to expedite the development and testing of these therapeutics.

The specific aims of my laboratory are:

1. To isolate and characterize RNA and DNA aptamers which block therapeutically relavent proteins such as those involved in cardiovascular diseases and immune modulation.

2. To develop RNA-based tumor targeting strategies for delivering siRNAs and miRNAs to tumor cells.

3. To reprogram cells using mRNA delivery.

4. To explore novel methods to control inflammation.

Education and Training

  • Ph.D., Cornell University, 1990

Selected Grants

Publications

Ray, Partha, Kristy L. Rialon-Guevara, Emanuela Veras, Bruce A. Sullenger, and Rebekah R. White. “Comparing human pancreatic cell secretomes by in vitro aptamer selection identifies cyclophilin B as a candidate pancreatic cancer biomarker..” J Clin Invest 122, no. 5 (May 2012): 1734–41. https://doi.org/10.1172/JCI62385.

Full Text

Sullenger, Bruce, Rebecca Woodruff, and Dougald M. Monroe. “Potent anticoagulant aptamer directed against factor IXa blocks macromolecular substrate interaction..” J Biol Chem 287, no. 16 (April 13, 2012): 12779–86. https://doi.org/10.1074/jbc.M111.300772.

Full Text

Nimjee, Shahid M., Jens D. Lohrmann, Haichen Wang, David J. Snyder, Thomas J. Cummings, Richard C. Becker, Sabah Oney, and Bruce A. Sullenger. “Rapidly regulating platelet activity in vivo with an antidote controlled platelet inhibitor..” Mol Ther 20, no. 2 (February 2012): 391–97. https://doi.org/10.1038/mt.2011.226.

Full Text

Pisetsky, David S., Jaewoo Lee, Kam W. Leong, and Bruce A. Sullenger. “Nucleic acid-binding polymers as anti-inflammatory agents: reducing the danger of nuclear attack..” Expert Rev Clin Immunol 8, no. 1 (January 2012): 1–3. https://doi.org/10.1586/eci.11.82.

Full Text

Brandal, Stephanie, Charlene M. Blake, Bruce A. Sullenger, and Yolanda M. Fortenberry. “Effects of plasminogen activator inhibitor-1-specific RNA aptamers on cell adhesion, motility, and tube formation..” Nucleic Acid Ther 21, no. 6 (December 2011): 373–81. https://doi.org/10.1089/nat.2011.0320.

Full Text

Ray, Partha, Bruce A. Sullenger, and Rebekah R. White. “AN RNA APTAMER IS A POTENTIAL BIOMARKER FOR PANCREATIC CANCER.” In Nucleic Acid Therapeutics, 21:A40–41. MARY ANN LIEBERT INC, 2011.

Scholars@Duke

Lee, Jaewoo, Jang Wook Sohn, Ying Zhang, Kam W. Leong, David Pisetsky, and Bruce A. Sullenger. “Nucleic acid-binding polymers as anti-inflammatory agents..” Proc Natl Acad Sci U S A 108, no. 34 (August 23, 2011): 14055–60. https://doi.org/10.1073/pnas.1105777108.

Full Text

Pages